Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations
The Oncologist · 06.11.2026
DOI: 10.1093/oncolo/oyag430 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 06.11.2026. Verfasst von Giulia Claire Giudice und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, Comprehensive Cancer Center IRCCS of Reggio Emilia, Reggio Emilia, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Despite improved outcomes with immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC), reliable biologically-driven prognostic markers remain needed. The CHOMET study evaluated tumor ABCA1/ABCG1 expression and their association with systemic lipid parameters, nutritional status, nephrectomy status and survival outcomes.
Methods
CHOMET was a retrospective observational biomarker study including mRCC patients undergoing first-line ICI-combinations. Tumor ABCA1 and ABCG1 expressions were assessed by immunohistochemistry (IHC). Serum total cholesterol (TC), triglycerides (TG), and the Controlling Nutritional Status score (CONUT) were collected. Publicly available transcriptomic datasets were used for exploratory bulk RNA-seq, immune deconvolution, and single-cell analyses.
Results
Among 86 patients (46 with IHC), high ABCA1 and ABCG1 expression was associated with shorter overall survival (OS, p = 0.003 and p = 0.01) and progression-free survival (PFS, p = 0.05 and p = 0.08). A composite nephrectomy-cholesterol score and a lower CONUT score were both significantly associated with improved PFS and OS. Exploratory bulk RNA-seq analyses suggested that high ABCA1 expression correlated with features of an immunosuppressive microenvironment enriched in M2 macrophages and depleted of CD8+ T cells, whereas high ABCG1 expression correlated with increased regulatory T cells. Exploratory single-cell analyses from four patients showed ABCA1 and ABCG1 expression across tumor-associated macrophages and tumor cells, with donor-specific pathway enrichment patterns involving immune signaling and cholesterol metabolism-related transcriptional programs.
Conclusions
ABCA1 and ABCG1 expression levels were associated with poorer outcomes in mRCC treated with ICI combinations and support a link between cholesterol transport programs and an immunosuppressive, metabolically reprogrammed tumor microenvironment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Unit, Comprehensive Cancer Center IRCCS of Reggio Emilia, Reggio Emilia, Italy.
- PhD Program Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
- Department of Oncology Science, University of Oklahoma College of Medicine, Oklahoma City, USA.
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
- Department of Medicine and Surgery, University of Parma, Parma, Italy.
- Pathology Unit, University Hospital of Parma, Parma, Italy.
ORCID-Profile: Giulia Claire Giudice
Zitieren
APA
Giudice, G. C., Abushukair, H. M., Mazzaschi, G., Tuttobene, P., Maffezzoli, M., Gnetti, L., Campanini, N., Iovane, G., Perrone, F., Pluchino, M., Rapacchi, E., Pinterpe, G., Travaglini, S., Marchitelli, R., Oh, T. G., Naqash, A. R., Santoni, M., Araldi, E., Pili, R., …, & Buti, S. (2026). Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations. The Oncologist. https://doi.org/10.1093/oncolo/oyag430
Vancouver
Giudice GC, Abushukair HM, Mazzaschi G, Tuttobene P, Maffezzoli M, Gnetti L, et al. Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations. The Oncologist. 2026. doi:10.1093/oncolo/oyag430
BibTeX
@article{Giudice2026,
author = {Giudice, Giulia Claire and Abushukair, Hassan Mohammed and Mazzaschi, Giulia and Tuttobene, Pietro and Maffezzoli, Michele and Gnetti, Letizia and Campanini, Nicoletta and Iovane, Giacomo and Perrone, Fabiana and Pluchino, Monica and Rapacchi, Elena and Pinterpe, Giada and Travaglini, Stefano and Marchitelli, Rosedwige and Oh, Tae Gyu and Naqash, Abdul Rafeh and Santoni, Matteo and Araldi, Elisa and Pili, Roberto and Perrone, Riccardo and Potì, Francesco and Berardi, Rossana and Pecci, Federica and Buti, Sebastiano},
title = {Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag430}
}
EUVIMED